NCT05826483 2023-04-24
Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
Guangzhou Institute of Respiratory Disease
Phase 1 Unknown
Clinical Trials
3 trialsNCT05430386 2023-02-14
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05223595 2022-02-04
A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Unknown